Austrian Breast & Colorectal Cancer Study Group
The Austrian Breast & Colorectal Cancer Study Group (ABCSG) is a Vienna-based non-profit academic research organization founded in 1984 that runs investigator-initiated and industry-sponsored clinical trials in breast and colorectal cancer across a network of Austrian study sites.
- Company typePrivate
- Founded2004
- HeadquartersVienna, Austria
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Austrian Breast & Colorectal Cancer Study Group does
The Austrian Breast & Colorectal Cancer Study Group (ABCSG) is a Vienna-based non-profit academic research organization (Verein) founded in 1984 that designs and conducts clinical trials in breast and colorectal cancer. It operates a national network of Austrian study sites, running both investigator-initiated trials (IITs) and industry-sponsored studies, and serves patients, Austrian oncologists, and global pharmaceutical sponsors. Leadership sits with President Prof. Michael Gnant, with translational research headed by Assoz. Prof. Mag. Dr. Martin Filipits. The work is supported by a senior KOL base and a study nurse/coordinator community that has been built across more than three decades.
ABCSG's core offerings break into three layers. The clinical operations layer covers protocol design, ethics and regulatory submissions, site activation, patient recruitment, data management, and publication of peer-reviewed results. The translational layer is anchored by the abcsg.research tumor bank, which supplies longitudinal breast and colorectal samples for correlative biomarker research. The educational layer is organized under abcsg.academy and includes Forum Study Nurses & Coordinators, Science into Practice, Science and Cases, Experts on Tour, the Interdisziplinärer Mamma Diskurs congress, and the abcsg.future early-career researcher program.
Revenue mechanics are those of an academic non-profit rather than a commercial CRO: funds flow from competitive research grants, per-patient and milestone-based pharmaceutical sponsorship fees for industry trials, and educational grants underwriting the academy and congress programs. Customer segments are effectively three: pharmaceutical sponsors (Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, Gilead, MSD, Stemline, Exact Sciences/Abbott, Agendia) for industry-sponsored trials, Austrian academic and public trial sites, and investigators/coordinators participating in the educational stack. There is no public pricing transparency and no equity capital structure.
Austrian Breast & Colorectal Cancer Study Group firmographics
Firmographics- Name
- Austrian Breast & Colorectal Cancer Study Group
- Legal name
- Verein zur Prävention und Therapie bösartiger Erkrankungen, Austrian Breast and Colorectal Cancer Study Group (ABCSG)
- Website
- https://abcsg.org
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- The Austrian Breast & Colorectal Cancer Study Group (ABCSG) is a Vienna-based non-profit academic research organization founded in 1984 that runs investigator-initiated and industry-sponsored clinical trials in breast and colorectal cancer across a network of Austrian study sites.
- Ownership category
- akta.pro rank
Austrian Breast & Colorectal Cancer Study Group industry classification
Industry- Product category
- Clinical Research Organization / Oncology Clinical Trials
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA)
- akta.pro secondary industries
- Healthcare Clinical Professions (CME/CE for Nurses, Allied Health, Pharmacy) (EDAAALAC), Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ)
Keywords
Where Austrian Breast & Colorectal Cancer Study Group is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
Austrian Breast & Colorectal Cancer Study Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Research Grants and Institutional Funding: ABCSG operates as an academic research organization funded through grants, pharmaceutical company partnerships, and institutional funding. The organization conducts clinical trials with support from pharmaceutical partners and government/institutional research grants.
Distribution channels1 record
Marketing channels12 records
Austrian Breast & Colorectal Cancer Study Group product offering
Product offeringCore offering
ABCSG is an independent academic non-profit cancer research organization that designs, coordinates, and runs clinical trials in breast and colorectal cancer through a network of Austrian study centers. It also manages a translational research program and tumor bank (abcsg.research) and offers accredited continuing medical education events and investigator training (abcsg.academy) for oncology professionals across Austria.
Product overview
ABCSG (Austrian Breast & Colorectal Cancer Study Group) is an independent academic cancer research organization comprising two entities: the association (Verein) and ABCSG GmbH. The organization's core offering is its clinical trials programs spanning breast and colorectal cancer research, including recruiting studies, treatment phase studies, follow-up studies, and translational research managed through abcsg.research. The portfolio is supported by extensive educational offerings including abcsg.academy for investigator certification, the Forum Study Nurses & Coordinators for clinical research staff training, and multiple event series (Jahrestagung, EXPERTS ON TOUR, Interdisziplinärer Mamma Diskurs, Science into Practice, Science and Cases, Post-SABCS). ABCSG also produces scientific content through its podcast 'Medizin im Kontext', Clinical Opinions publications, Science News, Surgery News video summaries, and annual reports. A password-protected Trial Data Port provides data access, while dedicated studies like ABCSG 50/BRCA-P and recently initiated studies (ABCSG 61/TEODOR, ABCSG 63/ERIKA, ABCSG 65/DEFINITIVE) represent active research projects.
Differentiator
Problem solved
Functional benefit
Brands
- abcsg.research: Translational research division of ABCSG focusing on biomarker research and tumor banking.
- abcsg.academy
- Forum Study Nurses & Coordinators
- abcsg.future
- Science into Practice
- Science and Cases
- Experts on Tour
- Interdisziplinärer Mamma Diskurs
Products and services
- ABCSG Clinical Trials Programs Independent academic clinical trial portfolio in breast and colorectal cancer, including recruiting studies, treatment-phase studies, follow-up studies, and translational research projects conducted across Austrian study centers. Intended for pharmaceutical sponsors, investigators, and cancer patients seeking access to innovative therapies.
Quantifiable outcome
- 30 publications in international peer-reviewed journals in 2025 - the most publication-intensive year in ABCSG history
Companies that use Austrian Breast & Colorectal Cancer Study Group
Customer profileSegments3 records
Ideal customer profiles3 records
Austrian Breast & Colorectal Cancer Study Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Austrian Breast & Colorectal Cancer Study Group partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core.
- Roche AustriacorePharmaceutical partner supporting ABCSG clinical trials and educational activities. Roche has been a longstanding supporter of ABCSG research initiatives and annual meetings.
- NovartiscorePharmaceutical partner providing support for ABCSG educational programs and clinical research activities. Novartis sponsors Experts on Tour and other ABCSG events.
- PfizercorePharmaceutical partner supporting ABCSG clinical trials and continuing medical education activities.
- Lilly (Eli Lilly)corePharmaceutical partner sponsoring ABCSG events and supporting oncology research and education in Austria.
- AstraZenecacorePharmaceutical partner supporting ABCSG clinical research and educational activities.
- Daiichi SankyocorePharmaceutical partner sponsoring ABCSG Experts on Tour educational events.
- Gilead SciencescorePharmaceutical partner supporting ABCSG events and activities.
- MSD (Merck Sharp & Dohme)corePharmaceutical partner sponsoring ABCSG educational activities.
- Stemline TherapeuticscorePharmaceutical partner supporting ABCSG events.
- Exact Sciences (Abbott)coreDiagnostic and pharmaceutical partner sponsoring ABCSG educational activities.
- AgendiacoreMolecular diagnostics company providing genomic testing services for breast cancer research, sponsoring ABCSG educational activities.
- SOLTI Cancer Research GroupcoreSpanish academic oncology research group collaborating with ABCSG on European breast cancer research initiatives. ABCSG participated in the SOLTI Young European Workshop in Barcelona in June 2026.
- Österreichische Gesellschaft für Senologie (Austrian Society of Senology)coreProfessional society collaborating with ABCSG on the annual Interdisziplinärer Mamma Diskurs educational event.
- Österreichisches Onkologie Forum (Austrian Oncology Forum)coreIndependent think tank of the Austrian Society for Hematology and Medical Oncology (OeGHO) that developed a joint position paper with ABCSG to strengthen clinical trials in Austria.
- Forum Study Nurses & Coordinatorscore
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Austrian Breast & Colorectal Cancer Study Group competitors and assessment
Company assessmentBroad incumbents
- Unicancer: French federation of comprehensive cancer centers running investigator-initiated clinical trials. Comparable to ABCSG as an academic, non-profit clinical research organization but with a broader tumor scope and national French footprint.
- BIG (Breast International Group): International non-profit network coordinating large-scale academic breast cancer trials worldwide. Operates as an umbrella to which many country-level groups contribute; comparable to ABCSG in mission and academic spirit but far larger and globally networked.
- EORTC (European Organisation for Research and Treatment of Cancer): Pan-European academic clinical cancer research organization headquartered in Belgium, running multi-tumor clinical trials across hundreds of European sites. Comparable as a translational/academic oncology trial body, but far larger and broader than ABCSG's Austria-only, two-indication focus.
Direct peers
- NSABP Foundation (National Surgical Adjuvant Breast and Bowel Project): US-based academic research organization running breast and colorectal cancer trials since the 1970s. Nearly identical therapeutic focus (breast and bowel/colorectal), investigator-initiated trials, and translational research portfolio, making it a strong functional analog to ABCSG.
- IBCSG (International Breast Cancer Study Group): International non-profit academic research group running large-scale breast cancer trials across multiple countries. Comparable mission, governance, and funding model (investigator-initiated trials, pharma-supported) as ABCSG, with a global vs. Austria-centric footprint.
- GEICAM (Spanish Breast Cancer Research Group): Spanish non-profit breast cancer research group running academic clinical trials and translational studies. Closely comparable to ABCSG in terms of disease focus, non-profit academic structure, and reliance on pharma sponsorship for trials and education.
- SAKK (Swiss Group for Clinical Cancer Research): Swiss non-profit academic research organization coordinating investigator-initiated oncology trials across Swiss centers. Functionally analogous to ABCSG, with a slightly broader indication set and a neighboring-country profile.
- SOLTI Cancer Research Group: Spanish academic oncology research group focused on breast cancer clinical trials, with which ABCSG already collaborates via the Young European Workshop. Structurally equivalent: an independent, non-profit, breast-cancer-focused academic research organization running its own investigator-initiated trials and educational programs.
Regional players
- Arbeitsgemeinschaft Deutscher Tumorzentren (ADT): German association of regional tumor centers coordinating oncology research and quality assurance. Shares ABCSG's academic, multi-center coordination model but operates in a different country and a broader tumor mix.
- AGO (Arbeitsgemeinschaft Gynäkologische Onkologie): German breast and gynecological cancer research and guideline group running academic trials and CME programs. Directly comparable in oncology focus and CME-driven model, with a German rather than Austrian footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Austrian Breast & Colorectal Cancer Study Group social profiles
Digital presenceAustrian Breast & Colorectal Cancer Study Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Austrian Breast & Colorectal Cancer Study Group leadership team
Management profileNumber of profiles
Profiles5 records
Austrian Breast & Colorectal Cancer Study Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Austrian Breast & Colorectal Cancer Study Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Austrian Breast & Colorectal Cancer Study Group
What does Austrian Breast & Colorectal Cancer Study Group do?
ABCSG is an independent academic non-profit cancer research organization that designs, coordinates, and runs clinical trials in breast and colorectal cancer through a network of Austrian study centers. It also manages a translational research program and tumor bank (abcsg.research) and offers accredited continuing medical education events and investigator training (abcsg.academy) for oncology professionals across Austria.
Is Austrian Breast & Colorectal Cancer Study Group a public or private company?
Austrian Breast & Colorectal Cancer Study Group is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Austrian Breast & Colorectal Cancer Study Group founded?
Austrian Breast & Colorectal Cancer Study Group was founded in 2004. It employs 51 to 100 people.
Where is Austrian Breast & Colorectal Cancer Study Group based?
Austrian Breast & Colorectal Cancer Study Group is headquartered in Vienna, Austria, in the Europe region.
How does Austrian Breast & Colorectal Cancer Study Group make money?
One revenue line is on record: research Grants and Institutional Funding.
Who are Austrian Breast & Colorectal Cancer Study Group's main competitors?
Broad incumbents on record are Unicancer, BIG (Breast International Group) and EORTC (European Organisation for Research and Treatment of Cancer). Direct peers are NSABP Foundation (National Surgical Adjuvant Breast and Bowel Project), IBCSG (International Breast Cancer Study Group), GEICAM (Spanish Breast Cancer Research Group), SAKK (Swiss Group for Clinical Cancer Research) and SOLTI Cancer Research Group. Regional players are Arbeitsgemeinschaft Deutscher Tumorzentren (ADT) and AGO (Arbeitsgemeinschaft Gynäkologische Onkologie).
Does Austrian Breast & Colorectal Cancer Study Group have an API?
No public API is recorded for Austrian Breast & Colorectal Cancer Study Group.
What industry is Austrian Breast & Colorectal Cancer Study Group in?
Austrian Breast & Colorectal Cancer Study Group's product category is Clinical Research Organization / Oncology Clinical Trials. Its primary akta.pro industry code is HLAFAAAA, Academic Medical Centers (AMCs) & Teaching Hospitals, with a secondary code of EDAAALAC, Healthcare Clinical Professions (CME/CE for Nurses, Allied Health, Pharmacy). Its NAICS code is 541714 and its SIC code is 8731.